Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

키워드

참고문헌 (135)

1. Marin-Acevedo JA, "Cancer immunotherapy beyond immune checkpoint inhibitors", J Hematol Oncol, 11, pp.8~ (2018)
2. McLane LM, "CD8 T cell exhaustion during chronic viral infection and cancer", Annu Rev Immunol, 37, pp.457~495 (2019)
3. Crawford A, "Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection", Immunity, 40, pp.289~302 (2014)
4. Singer M, "A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells", Cell, 166, pp.1500~1511 (2016)
5. Tirosh I, "Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq", Science, 352, pp.189~196 (2016)
6. Chen L, "Molecular mechanisms of T cell co-stimulation and co-inhibition", Nat Rev Immunol, 13, pp.227~242 (2013)
7. Jenkins MK, "Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells", J Immunol, 140, pp.3324~3330 (1988)
8. Mueller DL, "An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness", J Immunol, 142, pp.2617~2628 (1989)
9. Jenkins MK, "CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells", J Immunol, 147, pp.2461~2466 (1991)
10. Linsley PS, "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7", BB-1, 1990, pp.87, 5031~5035
11. Tian R, "Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor", Proc Natl Acad Sci U S A, 112, pp.E1594~ (2015)
12. Fraser JD, "Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28", Science, 251, pp.313~316 (1991)
13. June CH, "T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression", Mol Cell Biol, 7, pp.4472~4481 (1987)
14. Esensten JH, "CD28 costimulation : from mechanism to therapy", Immunity, 44, pp.973~988 (2016)
15. Strioga M, "CD8+ CD28-and CD8+ CD57+ T cells and their role in health and disease", Immunology, 134, pp.17~32 (2011)
16. Hui E, "T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition", Science, 355, pp.1428~1433 (2017)
17. Rudd CE, "CD28 and CTLA-4 coreceptor expression and signal transduction", Immunol Rev, 229, pp.12~26 (2009)
18. Tsukishiro T, "Rapid turnover of the CD8+CD28-T-cell subset of effector cells in the circulation of patients with head and neck cancer", Cancer Immunol Immunother, 52, pp.599~607 (2003)
19. Filaci G, "CD8+ CD28-T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers", J Immunol, 179, pp.4323~4334 (2007)
20. Meloni F, "Foxp3 expressing CD4+ CD25+ and CD8+ CD28-T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma", Hum Immunol, 67, pp.1~12 (2006)
21. Kamphorst AO, "Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent", Science, 355, pp.1423~1427 (2017)
22. Casado JG, "CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype", Cancer Immunol Immunother, 54, pp.1162~1171 (2005)
23. Huff WX, "The evolving role of CD8+CD28-immunosenescent T cells in cancer immunology", Int J Mol Sci, 20, pp.2810~ (2019)
24. Suntharalingam G, "Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412", N Engl J Med, 355, pp.1018~1028 (2006)
25. Tyrsin D, "From TGN1412 to TAB08 : the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis", Clin Exp Rheumatol, 34, pp.45~48 (2016)
26. Tang XY, "Third-generation CD28", 4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia : a non-randomised, open-label phase I trial protocol, 2016, pp.6, e013904~
27. Cabo M, "Trial Watch : immunostimulatory monoclonal antibodies for oncological indications", OncoImmunology, 6, pp.e1371896~ (2017)
28. Hutloff A, "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28", Nature, 397, pp.263~266 (1999)
29. McAdam AJ, "Mouse inducible costimulatory molecule(ICOS)expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells", J Immunol, 165, pp.5035~5040 (2000)
30. Peach RJ, "Complementarity determining region 1(CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1", J Exp Med, 180, pp.2049~2058 (1994)
31. Wikenheiser DJ, "ICOS co-stimulation : friend or foe", Front Immunol, 7, pp.304~ (2016)
32. McHugh RS, "CD4+CD25+ immunoregulatory T cells : gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor", Immunity, 16, pp.311~323 (2002)
33. Tafuri A, "ICOS is essential for effective T-helper-cell responses", Nature, 409, pp.105~109 (2001)
34. Le KS, "CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas", Blood Adv, 2, pp.1889~1900 (2018)
35. Metzger TC, "ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection", Cancer Res, 76, pp.3684~3689 (2016)
36. Im SJ, "Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy", Nature, 537, pp.417~421 (2016)
37. Beyrend G, "PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors", J Immunother Cancer, 7, pp.217~ (2019)
38. Kamphorst AO, "Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients", Proc Natl Acad Sci U S A, 114, pp.4993~4998 (2017)
39. Zhang Y, "The clinical impact of ICOS signal in colorectal cancer patients", OncoImmunology, 5, pp.e1141857~ (2016)
40. Soldevilla MM, "ICOS costimulation at the tumor site in combination with ctla-4 blockade therapy elicits strong tumor immunity", Mol Ther, 27, pp.1878~1891 (2019)
41. Fan X, "Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy", J Exp Med, 211, pp.715~725 (2014)
42. Chen Q, "ICOS signal facilitates Foxp3 transcription to favor suppressive function of regulatory T cells", Int J Med Sci, 15, pp.666~673 (2018)
43. Amatore F, "Inducible co-stimulator(ICOS)as a potential therapeutic target for anti-cancer therapy", Expert Opin Ther Targets, 22, pp.343~351 (2018)
44. Burns GF, "TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors", J Exp Med, 161, pp.1063~1078 (1985)
45. Gilfillan S, "DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors", J Exp Med, 205, pp.2965~2973 (2008)
46. Hou S, "CD226 protein is involved in immune synapse formation and triggers natural killer(NK)cell activation via its first extracellular domain", J Biol Chem, 289, pp.6969~6977 (2014)
47. Chan CJ, "Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer", Curr Opin Immunol, 24, pp.246~251 (2012)
48. Lozano E, "The TIGIT", CD226 axis regulates human T cell function, 2012, pp.188, 3869~3875
49. Ramsbottom KM, "Cutting edge : DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity", J Immunol, 192, pp.553~557 (2014)
50. Johnston RJ, "The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function", Cancer Cell, 26, pp.923~937 (2014)
51. Chauvin JM, "TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients", J Clin Invest, 125, pp.2046~2058 (2015)
52. Josefsson SE, "T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling", Clin Cancer Res, 24, pp.870~881 (2018)
53. Guillerey C, "TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma", Blood, 132, pp.1689~1694 (2018)
54. Fourcade J, "CD226 opposes TIGIT to disrupt Tregs in melanoma", JCI Insight, 3, pp.e121157~ (2018)
55. Guillerey C, "Immunosurveillance and therapy of multiple myeloma are CD226 dependent", J Clin Invest, 125, pp.2077~2089 (2015)
56. Kane LP, "T cell Ig and mucin domain proteins and immunity", J Immunol, 184, pp.2743~2749 (2010)
57. Du P, "Immune regulation and antitumor effect of TIM-1", J Immunol Res, 2016, pp.8605134~ (2016)
58. Meyers JH, "TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation", Nat Immunol, 6, pp.455~464 (2005)
59. Kobayashi N, "TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells", Immunity, 27, pp.927~940 (2007)
60. Degauque N, "Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice", J Clin Invest, 118, pp.735~741 (2008)
61. Xiao S, "Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells", Eur J Immunol, 41, pp.1539~1549 (2011)
62. Musgrave BL, "CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function : anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition", adhesion, and cytotoxicity, 2003, pp.23, 67~81
63. Wild MK, "Tumor therapy with bispecific antibody : the targeting and triggering steps can be separated employing a CD2-based strategy", J Immunol, 163, pp.2064~2072 (1999)
64. Cheadle EJ, "Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells", Gene Ther, 19, pp.1114~1120 (2012)
65. Valdez PA, "NTB-A, a new activating receptor in T cells that regulates autoimmune disease", J Biol Chem, 279, pp.18662~18669 (2004)
66. Flaig RM, "Cutting edge : NTB-A activates NK cells via homophilic interaction", J Immunol, 172, pp.6524~6527 (2004)
67. Miller BC, "Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade", Nat Immunol, 20, pp.326~336 (2019)
68. Eisenberg G, "Soluble SLAMF6 receptor induces strong CD8+ T-cell effector function and improves anti-melanoma activity in vivo", Cancer Immunol Res, 6, pp.127~138 (2018)
69. Goodwin RG, "Molecular cloning of a ligand for the inducible T cell gene 4-1BB : a member of an emerging family of cytokines with homology to tumor necrosis factor", Eur J Immunol, 23, pp.2631~2641 (1993)
70. Vinay DS, "Role of 4-1BB in immune responses", Semin Immunol, 10, pp.481~489 (1998)
71. Menk AV, "4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses", J Exp Med, 215, pp.1091~1100 (2018)
72. Chester C, "Immunotherapy targeting 4-1BB : mechanistic rationale, clinical results, and future strategies", Blood, 131, pp.49~57 (2018)
73. Chester C, "4-1BB agonism : adding the accelerator to cancer immunotherapy", Cancer Immunol Immunother, 65, pp.1243~1248 (2016)
74. Drenkard D, "CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity", FASEB J, 21, pp.456~463 (2007)
75. Teijeira Á, "CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells", FASEB J, 26, pp.3380~3392 (2012)
76. Palazón A, "Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes", Cancer Res, 71, pp.801~811 (2011)
77. Saoulli K, "CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand", J Exp Med, 187, pp.1849~1862 (1998)
78. Wolfl M, "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities", Blood, 110, pp.201~210 (2007)
79. Hyung‐Don Kim, "4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8 + T Cells in Hepatocellular Carcinoma", Hepatology, 71(3), pp.955~971 (2020), Wiley[DOI]
80. Ye Q, "CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor", Clin Cancer Res, 20, pp.44~55 (2014)
81. Thommen DS, "A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade", Nat Med, 24, pp.994~1004 (2018)
82. Williams JB, "The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment", J Exp Med, 214, pp.381~400 (2017)
83. Weigelin B, "Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb", Proc Natl Acad Sci U S A, 112, pp.7551~7556 (2015)
84. Houot R, "Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion", Blood, 114, pp.3431~3438 (2009)
85. Wilcox RA, "Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors", J Clin Invest, 109, pp.651~659 (2002)
86. Mayes PA, "The promise and challenges of immune agonist antibody development in cancer", Nat Rev Drug Discov, 17, pp.509~527 (2018)
87. Qi X, "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity", Nat Commun, 10, pp.2141~ (2019)
88. Hinner MJ, "Tumor-localized costimulatory t-cell engagement by the 4-1bb", her2 bispecific antibody-anticalin fusion prs-343, 2019, pp.25, 5878~5889
89. Claus C, "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy", Sci Transl Med, 11, pp.eaav5989~ (2019)
90. Labrijn AF, "Bispecific antibodies : a mechanistic review of the pipeline", Nat Rev Drug Discov, 18, pp.585~608 (2019)
91. Linch SN, "Ox40 agonists and combination immunotherapy : Putting the pedal to the metal", Front Oncol, 5, pp.34~ (2015)
92. Ishii N, "OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology", Adv Immunol, 105, pp.63~98 (2010)
93. Sugamura K, "Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40", Nat Rev Immunol, 4, pp.420~431 (2004)
94. Song J, "The costimulation-regulated duration of PKB activation controls T cell longevity", Nat Immunol, 5, pp.150~158 (2004)
95. Song J, "Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion", Immunity, 22, pp.621~631 (2005)
96. Song J, "Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival", J Immunol, 180, pp.7240~7248 (2008)
97. Ito T, "OX40 ligand shuts down IL-10-producing regulatory T cells", Proc Natl Acad Sci U S A, 103, pp.13138~13143 (2006)
98. Willoughby J, "OX40 : structure and function-what questions remain", Mol Immunol, 83, pp.13~22 (2017)
99. Kjaergaard J, "Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth", Cancer Res, 60, pp.5514~5521 (2000)
100. Linch SN, "Combination OX40 agonism", CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice, 2016, pp.113, E319~
101. Ladányi A, "T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma", Clin Cancer Res, 10, pp.521~530 (2004)
102. Petty JK, "Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40(CD134)", Am J Surg, 183, pp.512~518 (2002)
103. Boettler T, "OX40 facilitates control of a persistent virus infection", PLoS Pathog, 8, pp.e1002913~ (2012)
104. Peng W, "Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma", Clin Cancer Res, 25, pp.6406~6416 (2019)
105. Curti BD, "OX40 is a potent immune-stimulating target in late-stage cancer patients", Cancer Res, 73, pp.7189~7198 (2013)
106. Piconese S, "OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection", J Exp Med, 205, pp.825~839 (2008)
107. Polesso F, "OX40 agonist tumor immunotherapy does not impact regulatory T cell suppressive function", J Immunol, 203, pp.2011~2019 (2019)
108. Redmond WL, "Combined targeting of costimulatory(OX40)and coinhibitory(CTLA-4)pathways elicits potent effector T cells capable of driving robust antitumor immunity", Cancer Immunol Res, 2, pp.142~153 (2014)
109. Guo Z, "PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer", PLoS One, 9, pp.e89350~ (2014)
110. Shrimali RK, "Concurrent pd-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis", Cancer Immunol Res, 5, pp.755~766 (2017)
111. Redmond WL, "Dual anti-OX40", IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression, 2012, pp.7, e34467~
112. Kvarnhammar AM, "The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation", J Immunother Cancer, 7, pp.103~ (2019)
113. Knee DA, "Rationale for anti-GITR cancer immunotherapy", Eur J Cancer, 67, pp.1~10 (2016)
114. Nocentini G, "GITR : a modulator of immune response and inflammation", Adv Exp Med Biol, 647, pp.156~173 (2009)
115. Snell LM, "CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection", J Immunol, 185, pp.7223~7234 (2010)
116. Kim IK, "Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells", Nat Med, 21, pp.1010~1017 (2015)
117. Zhan Y, "Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-kappaB and NFAT", J Immunol, 181, pp.5405~5413 (2008)
118. Clouthier DL, "GITR intrinsically sustains early type 1 and late follicular helper CD4 T cell accumulation to control a chronic viral infection", PLoS Pathog, 11, pp.e1004517~ (2015)
119. Vence L, "Characterization and comparison of GITR expression in solid tumors", Clin Cancer Res, 25, pp.6501~6510 (2019)
120. Sabharwal SS, "GITR agonism enhances cellular metabolism to support CD8+ T-cell proliferation and effector cytokine production in a mouse tumor model", Cancer Immunol Res, 6, pp.1199~1211 (2018)
121. Cho JS, "Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity", Cancer Immunol Immunother, 58, pp.1057~1069 (2009)
122. Cohen AD, "Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation", PLoS One, 5, pp.e10436~ (2010)
123. Kim YH, "Authentic GITR signaling fails to induce tumor regression unless Foxp3+ regulatory T cells are depleted", J Immunol, 195, pp.4721~4729 (2015)
124. Wang B, "Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype", Sci Immunol, 3, pp.eaat7061~ (2018)
125. Narumi K, "Local administration of GITR agonistic antibody induces a stronger antitumor immunity than systemic delivery", Sci Rep, 9, pp.5562~ (2019)
126. Ahrends T, "CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness", Immunity, 47, pp.848~861 (2017)
127. Keller AM, "Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity", Immunity, 29, pp.934~946 (2008)
128. Claus C, "CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth", Cancer Res, 72, pp.3664~3676 (2012)
129. Wasiuk A, "CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy", J Immunol, 199, pp.4110~4123 (2017)
130. He LZ, "Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice", J Immunol, 191, pp.4174~4183 (2013)
131. Ward-Kavanagh LK, "The TNF receptor superfamily in co-stimulating and co-inhibitory responses", Immunity, 44, pp.1005~1019 (2016)
132. Twohig JP, "The death receptor 3", TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity, 2012, pp.26, 3575~3586
133. Meylan F, "TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation", Immunol Rev, 244, pp.188~196 (2011)
134. Richard AC, "The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells", J Immunol, 194, pp.3567~3582 (2015)
135. Tam EM, "Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity", Sci Transl Med, 11, pp.eaax0720~ (2019)

관련 논문AI추천